Trial Profile
A phase I study of the safety and pharmacokinetics of higher-dose Icotinib in patients with advanced non-small cell lung cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Nov 2017
Price :
$35
*
At a glance
- Drugs Icotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Betta Pharmaceuticals Co Ltd
- 17 Nov 2017 New trial record